Business school incubator start-up raises EUR 16 million biotech investment

An entrepreneurial incubator set up through an international business school has raised a large biotech investment for developing innovative treatments for Type 2 diabetes sufferers. The school aims to stimulate the social responsibility of its participants, providing the support needed to achieve business success across various cultural and economic systems. Training is based both on theory and on day-to-day company management, founded on teaching innovation and an entrepreneurial approach to management education.

A company set up through international business school EMLYON’s Entrepreneurial Incubator has raised one of the largest bio-tech investments since 2005. Launched in June 2008, the EMLYON Incubator currently includes 31 companies with an operational budget of about EUR 500, 000.

Poxel, a company that was founded in 2009 and is developing innovative treatments for Type 2 diabetes sufferers, secured a EUR 16 million cash injection from several investors.

The company, which is already seeing promising results from clinical trials of its treatments, stands to help 285 million diabetics worldwide, a number that is currently increasing by 7 million annually. Further, the company is expected to develop future diabetes treatments that could also aid cardiovascular problems and infectious diseases.

Accompanied by the EMLYON Business School Incubator since its launch, the company profited from its support during the difficult period of fund raising. Poxel is a good starting point for developing strategies of activity in sectors where millions of Euros may be needed in financing. Since 1984 more tha 550 companies and 10, 000 jobs have been created via the Centre for Entrepreneurship.

EMLYON aims to stimulate the social responsibility of its participants, giving them all the support needed to achieve business success in the various cultural and economic systems around the world.

Filed in: Accompanying leaders in their transformation
Tags: , ,

Leave a Reply

Trackback URL | RSS Feed for This Entry

You must be logged in to post a comment.